Budget impact at cost-effectiveness threshold prices
“The proportion of the eligible population that could be treated before reaching the potential budget impact threshold was not estimated at threshold prices because no threshold price would make tavapadon as first-line treatment cost-effective at any of the evaluated thresholds.” (opens the source at this quote in a new tab)
“At the $50,000, $100,000, $150,000, and $200,000 per evLY threshold prices ($6,336, $6,598, $6,861, and $7,123 from the health care system perspective, and $4,501, $4,764, $5,026, and $5,289 from the modified societal perspective), 100% of the population could be treated before reaching the potential budget impact threshold.” (opens the source at this quote in a new tab)